Grace Therapeutics, Inc. (GRCE) Cash Flow Statement
Where GRCE’s cash came from and went, FY2026
March 31, 2026 · U.S. dollars- Cash from operations
- −$8.9M
- Capital expenditures
- $0
- Free cash flow
- −$8.9M
- Returned to shareholders
- —
- Change in cash
- −$5.2M cash at year-end $17.0M
Cash from operations
−$8.9M
Other financing
+$3.7M
Change in cash
−$5.2M
Drawn to scale: where the cash came from and how it was used. Hover for values.
GRCE operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
GRCE cash flow trends, FY2017–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$6.9MFY2017 | −$8.9MFY2026 | — | |
| Capital expenditures | $2.6MFY2017 | $0FY2026 | −100.0% | |
| Free cash flow | −$9.5MFY2017 | −$8.9MFY2026 | — | |
| Stock-based compensation | $719,368FY2018 | $798,000FY2026 | +1.3%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
GRCE cash flow by activity
OperatingInvestingFinancingChange in cash
GRCE net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
GRCE cash flow statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$7.8M | −$9.6M | −$12.9M | −$42.4M | −$9.8M | −$24.7M | −$36.1M | −$39.4M | −$16.7M | −$10.6M |
| Depreciation & amortization | $7,000 | $7,000 | $11,000 | $124,000 | $0 | $1.2M | $3.3M | $2.3M | $2.1M | $2.6M |
| Stock-based compensation | $798,000 | $730,000 | $913,000 | $1.8M | $1.3M | $1.5M | $2.8M | $777,000 | $719,368 | — |
| Change in working capital | $719,000 | $342,000 | −$1.3M | $181,000 | −$2.8M | −$7.5M | −$4.5M | $6.2M | $2.8M | $805,356 |
| Other non-cash items | −$2.6M | −$6.4M | $876,000 | $24.4M | −$6.0M | $11.6M | $2.1M | $5.3M | $1.4M | $240,392 |
| Cash from operating activities | −$8.9M | −$14.9M | −$12.3M | −$15.9M | −$17.2M | −$18.0M | −$32.4M | −$24.8M | −$9.7M | −$6.9M |
| Investing activities | ||||||||||
| Capital expenditures | $0 | $0 | −$22,000 | −$17,000 | $0 | −$86,681 | −$450,930 | −$534,000 | −$352,328 | −$2.6M |
| Investments (net) | $0 | $0 | $104,000 | $13.2M | −$3.5M | −$9.9M | — | — | — | — |
| Acquisitions & other investing | — | — | $22,000 | $17,000 | $0 | −$2.4M | $12.0M | −$8.9M | $34,072 | $9.4M |
| Cash from investing activities | — | — | $104,000 | $13.2M | −$3.5M | −$12.4M | $11.5M | −$9.4M | −$318,256 | $6.9M |
| Financing activities | ||||||||||
| Share repurchases & issuance (net) | — | — | — | — | — | — | — | — | −$30,973 | — |
| Shares issued | $0 | $15.0M | $7.3M | $304,000 | $0 | $59.3M | $0 | $0 | $0 | $0 |
| Other financing | $3.7M | −$967,000 | $21,000 | $0 | $0 | $15.4M | $18.6M | $45.7M | $8.9M | $7.0M |
| Cash from financing activities | $3.7M | $14.0M | $7.4M | $304,000 | $0 | $74.7M | $18.6M | $45.7M | $8.8M | $7.0M |
| Summary | ||||||||||
| Net change in cash | −$5.2M | −$872,000 | −$4.9M | −$2.5M | −$20.6M | $46.1M | −$3.7M | $10.4M | −$1.2M | −$3.0M |
| Cash at end of period | $17.0M | $22.1M | $23.0M | $27.9M | $30.3M | $64.0M | $20.1M | $16.9M | $6.4M | $7.6M |
| Free cash flow | −$8.9M | −$14.9M | −$12.4M | −$15.9M | −$17.2M | −$18.1M | −$32.9M | −$25.3M | −$10.0M | −$9.5M |
| Free cash flow margin | — | — | — | — | — | −5,843.5% | — | — | — | — |
| Capex / revenue | — | — | — | — | — | 28.0% | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$15.8M | −$1.2M | −$2.3M | −$938,000 | −$3.4M | $636,000 | −$4.2M | −$3.4M | −$2.6M | −$3.2M | −$2.4M | −$3.3M |
| Depreciation & amortization | $2,000 | $2,000 | $3,000 | $1,000 | $2,000 | $2,000 | $2,000 | $2,000 | $1,000 | $1,000 | $1,000 | $2,000 |
| Stock-based compensation | $105,000 | −$24,000 | $314,000 | $206,000 | $302,000 | $130,000 | $160,000 | $202,000 | $238,000 | $229,000 | $326,000 | $280,000 |
| Change in working capital | −$1.1M | $1.0M | −$88,785 | −$983,501 | $770,000 | −$66,000 | −$695,000 | $202,000 | $901,000 | $704,000 | $506,000 | −$464,000 |
| Other non-cash items | $13.5M | −$1.5M | −$131,576 | −$1.4M | $487,000 | −$3.7M | $573,000 | −$1.2M | −$2.1M | $144,000 | −$334,000 | $1.3M |
| Cash from operating activities | −$3.2M | −$1.7M | −$2.2M | −$3.2M | −$1.8M | −$3.0M | −$4.1M | −$4.2M | −$3.6M | −$2.1M | −$1.9M | −$2.1M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | $0 | −$0 | $0 | $0 | −$5 | −$4 | $0 | −$22,000 | $0 | $0 |
| Investments (net) | — | $0 | $0 | $0 | $0 | $0 | $15,000 | $0 | −$15,000 | $6.5M | −$6.6M | $110,000 |
| Acquisitions & other investing | — | — | — | — | — | — | $5 | −$20 | $0 | $22,000 | $0 | $0 |
| Cash from investing activities | — | — | — | — | — | — | $15,000 | −$23 | −$15,000 | $6.5M | −$6.6M | $110,000 |
| Financing activities | ||||||||||||
| Shares issued | $0 | $0 | $0 | $0 | $0 | $15.0M | $0 | $0 | $0 | $0 | $0 | $7.3M |
| Other financing | $0 | −$769 | $4.0M | −$769 | −$327,000 | −$967,000 | $0 | $0 | $0 | $61,028 | −$65,333 | $21,000 |
| Cash from financing activities | $0 | −$769 | $4.0M | −$769 | −$327,000 | $14.0M | $0 | $0 | $0 | $61,028 | −$65,333 | $7.4M |
| Summary | ||||||||||||
| Net change in cash | −$3.2M | −$1.7M | $1.8M | −$3.1M | −$2.1M | $11.1M | −$4.1M | −$4.2M | −$3.6M | $4.5M | −$8.4M | $5.4M |
| Cash at end of period | $13.8M | $17.0M | $18.7M | $16.9M | $20.0M | $22.1M | $11.1M | $15.2M | $19.4M | $23.0M | $18.5M | $27.0M |
| Free cash flow | −$3.2M | −$1.7M | −$2.2M | −$3.2M | −$1.8M | −$3.0M | −$4.1M | −$4.2M | −$3.6M | −$2.1M | −$1.9M | −$2.1M |
| Free cash flow margin | — | — | — | — | — | −36,925.0% | — | — | — | — | — | — |
| Capex / revenue | — | — | — | — | — | 0.0% | — | — | — | — | — | — |
| Operating cash flow / net income | — | — | — | — | — | −4.64 | — | — | — | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
GRCE cash generation
In fiscal 2026 (ended March 31, 2026), Grace Therapeutics generated -$8.9 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$8.9 million. Cash and equivalents fell by $5.2 million over the year.
Related: GRCE income statement, GRCE balance sheet. See the GRCE stock overview for the latest quote and news.
GRCE cash flow FAQ
What is Grace Therapeutics's free cash flow?
Grace Therapeutics's free cash flow was -$8.9 million in fiscal 2026: -$8.9 million of operating cash flow minus $0 of capital expenditures It was -$14.9 million a year earlier..
How much cash does Grace Therapeutics generate from operations?
Grace Therapeutics generated -$8.9 million of cash from operating activities in fiscal 2026.